Temedica and Roche Pharma AG announce the launch of the digital patient companion, Retinora, as part of a close and long-standing cooperation.
The digital companion app Retinora is specifically designed for those affected by wet age-related macular degeneration (nAMD) and diabetic macular edema (DME), and is the result of intense collaboration with affected individuals and technology experts.
Diabetic macular edema (DME) is a common swelling of the retina in the eye that occurs as a consequence of diabetes mellitus and can lead to vision loss up to blindness. Age-related macular degeneration (nAMD) causes damage to the retina in the macula area. This significantly impairs the ability to see clearly and cannot be corrected by wearing glasses.
Retinora incorporates a wide range of features tailored to the individual needs and challenges of patients with eye diseases. These include optimized appointment scheduling with reminder functions and comprehensive information about retinal diseases to keep users informed about the latest diagnostic and treatment methods. In the future, the app will also integrate text-to-speech functions, color recognition, and other specialized features to enhance the daily independence of affected individuals.
Through connection to Temedica's Real-World Evidence platform, Permea, users regularly receive valuable insights generated from current research findings and the aggregation and analysis of various data sources. Additionally, app users have the opportunity to share their experiences for scientific research, thereby actively contributing to the improvement of care for patients with wet AMD and DME. All data are used under the strictest observance of the General Data Protection Regulation (GDPR) and with the explicit consent of the users.
“'Retinora' is already the second app that has been developed in cooperation between Roche and Temedica, based on Temedica’s unique app platform technology. With this development, we significantly contribute to the support and accompaniment of patients with macular diseases.“
“By combining technology and science, we now offer another comprehensive and individually tailored support that places patient well-being at the forefront.”
With the development of Retinora, Temedica and Roche underline their leading role in the digital health landscape and set a strong signal for growth and innovation in this sector. Retinora marks a significant advancement in promoting the independence and well-being of patients with nAMD and DME.
About Temedica
Temedica is a health insights company based in Munich. Since 2016, it operates Europe's leading ecosystem for real-world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.
Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit https://temedica.com/en/.
About Roche
Founded in1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
For further information and media inquiries, please contact:
Temedica GmbH
Anna Hauner
Corporate Communications
E-Mail: pr@temedica.com
T: + 49 175 431 030 1
Roche Pharma AG
Faten Gaber
Head of Communications & Public Affairs Roche Pharma AG
E-Mail: grenzach.communications@roche.com
Tel. +49 7624 14 4000